

Lu Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3475176/publications.pdf>

Version: 2024-02-01

229
papers

13,790
citations

41258

49
h-index

31759

101
g-index

240
all docs

240
docs citations

240
times ranked

20224
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. <i>Emerging Microbes and Infections</i> , 2020, 9, 382-385.	3.0	1,086
2	Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. <i>Cell Research</i> , 2020, 30, 343-355.	5.7	1,083
3	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. <i>Cellular and Molecular Immunology</i> , 2020, 17, 765-767.	4.8	564
4	Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. <i>Cell</i> , 2021, 184, 92-105.e16.	13.5	480
5	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. <i>Nature</i> , 2022, 603, 693-699.	13.7	460
6	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. <i>Science Advances</i> , 2019, 5, eaav4580.	4.7	393
7	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. <i>Cell Research</i> , 2021, 31, 126-140.	5.7	356
8	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. <i>Nature Communications</i> , 2014, 5, 3067.	5.8	324
9	Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. <i>Clinical Infectious Diseases</i> , 2022, 75, e822-e826.	2.9	322
10	SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. <i>Emerging Microbes and Infections</i> , 2022, 11, 277-283.	3.0	308
11	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 92.	7.1	263
12	MERS-CoV spike protein: a key target for antivirals. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 131-143.	1.5	236
13	Identification of Human Single-Domain Antibodies against SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 27, 891-898.e5.	5.1	227
14	Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. <i>Journal of Virology</i> , 2014, 88, 7796-7805.	1.5	212
15	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	2.6	211
16	Pulmonary surfactant biomimetic nanoparticles potentiate heterosubtypic influenza immunity. <i>Science</i> , 2020, 367, .	6.0	203
17	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27141-27147.	3.3	173
18	Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development. <i>Journal of Virology</i> , 2013, 87, 9939-9942.	1.5	168

#	ARTICLE	IF	CITATIONS
19	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	7.1	149
20	AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling. <i>Nature Microbiology</i> , 2018, 3, 302-309.	5.9	129
21	High neutralizing antibody titer in intensive care unit patients with COVID-19. <i>Emerging Microbes and Infections</i> , 2020, 9, 1664-1670.	3.0	129
22	Emerging SARS-CoV-2 variants expand species tropism to murines. <i>EBioMedicine</i> , 2021, 73, 103643.	2.7	127
23	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. <i>Cellular and Molecular Immunology</i> , 2020, 17, 554-554.	4.8	124
24	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. <i>Nature Communications</i> , 2017, 8, 15672.	5.8	115
25	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. <i>Cellular and Molecular Immunology</i> , 2016, 13, 180-190.	4.8	114
26	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. <i>Science</i> , 2022, 377, 428-433.	6.0	113
27	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	2.9	110
28	Additional molecular testing of saliva specimens improves the detection of respiratory viruses. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	101
29	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. <i>Virus Research</i> , 2014, 194, 200-210.	1.1	100
30	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, 1894-1903.	1.9	87
31	Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. <i>Lancet Microbe, The</i> , 2020, 1, e111-e118.	3.4	86
32	A genome-scale screen for synthetic drivers of T cell proliferation. <i>Nature</i> , 2022, 603, 728-735.	13.7	84
33	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. <i>Cell</i> , 2022, 185, 1389-1401.e18.	13.5	82
34	Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1 <i>H</i> -pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 Fusion Inhibitors Targeting gp41. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 572-579.	2.9	81
35	Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. <i>Microbes and Infection</i> , 2013, 15, 625-629.	1.0	79
36	Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China. <i>Microbes and Infection</i> , 2013, 15, 432-439.	1.0	78

#	ARTICLE	IF	CITATIONS
37	Antivirals with common targets against highly pathogenic viruses. <i>Cell</i> , 2021, 184, 1604-1620.	13.5	78
38	Engineered trimeric ACE2 binds viral spike protein and locks it in a "Three-up" conformation to potently inhibit SARS-CoV-2 infection. <i>Cell Research</i> , 2021, 31, 98-100.	5.7	76
39	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. <i>Nature Communications</i> , 2021, 12, 866.	5.8	73
40	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. <i>Journal of Virology</i> , 2016, 90, 57-67.	1.5	72
41	Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. <i>Viruses</i> , 2013, 5, 211-225.	1.5	64
42	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. <i>International Journal of Molecular Sciences</i> , 2018, 19, 487.	1.8	63
43	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. <i>Nature Microbiology</i> , 2022, 7, 1063-1074.	5.9	63
44	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 1074-1090.	1.0	61
45	A tailored extracellular matrix (ECM) - Mimetic coating for cardiovascular stents by stepwise assembly of hyaluronic acid and recombinant human type III collagen. <i>Biomaterials</i> , 2021, 276, 121055.	5.7	58
46	A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. <i>Retrovirology</i> , 2012, 9, 104.	0.9	57
47	Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. <i>Emerging Microbes and Infections</i> , 2022, 11, 543-547.	3.0	57
48	Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus Infection. <i>EBioMedicine</i> , 2017, 20, 193-201.	2.7	55
49	Receptor-binding domain-based subunit vaccines against MERS-CoV. <i>Virus Research</i> , 2015, 202, 151-159.	1.1	54
50	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
51	Receptor-binding domain as a target for developing SARS vaccines. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 2, S142-8.	0.6	52
52	Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or Microbicides. <i>Journal of Biological Chemistry</i> , 2010, 285, 25506-25515.	1.6	51
53	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. <i>Cell Host and Microbe</i> , 2017, 22, 471-483.e5.	5.1	48
54	In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. <i>Journal of Biological Chemistry</i> , 2011, 286, 3277-3287.	1.6	47

#	ARTICLE	IF	CITATIONS
55	Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket. <i>Viruses</i> , 2013, 5, 127-149.	1.5	46
56	Advancements in the development of subunit influenza vaccines. <i>Microbes and Infection</i> , 2015, 17, 123-134.	1.0	43
57	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1623-1630.	2.9	42
58	Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain during the Membrane Fusion Process. <i>Journal of Biological Chemistry</i> , 2008, 283, 16723-16731.	1.6	41
59	Testing of Middle East Respiratory Syndrome Coronavirus Replication Inhibitors for the Ability To Block Viral Entry. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 742-744.	1.4	41
60	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-11.	3.0	41
61	Identification of the HIV-1 gp41 Core-binding Motif in the Scaffolding Domain of Caveolin-1. <i>Journal of Biological Chemistry</i> , 2007, 282, 6143-6152.	1.6	40
62	Development of therapeutics for treatment of Ebola virus infection. <i>Microbes and Infection</i> , 2015, 17, 109-117.	1.0	40
63	Development of oncolytic virotherapy: from genetic modification to combination therapy. <i>Frontiers of Medicine</i> , 2020, 14, 160-184.	1.5	40
64	Injectable multifunctional hyaluronic acid/methylcellulose hydrogels for chronic wounds repairing. <i>Carbohydrate Polymers</i> , 2022, 289, 119456.	5.1	40
65	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. <i>Journal of Infection</i> , 2013, 66, 464-466.	1.7	39
66	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. <i>Virologica Sinica</i> , 2020, 35, 857-860.	1.2	39
67	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	7.1	38
68	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. <i>EBioMedicine</i> , 2021, 71, 103544.	2.7	38
69	Polyanionic Candidate Microbicides Accelerate the Formation of Semen-Derived Amyloid Fibrils to Enhance HIV-1 Infection. <i>PLoS ONE</i> , 2013, 8, e59777.	1.1	37
70	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. <i>Protein and Cell</i> , 2018, 9, 596-615.	4.8	37
71	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3843.	1.8	37
72	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. <i>Emerging Microbes and Infections</i> , 2012, 1, 1-8.	3.0	36

#	ARTICLE	IF	CITATIONS
73	Conjugation of a Nonspecific Antiviral Sapogenin with a Specific HIV Fusion Inhibitor: A Promising Strategy for Discovering New Antiviral Therapeutics. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7342-7354.	2.9	36
74	Zika virus infects renal proximal tubular epithelial cells with prolonged persistency and cytopathic effects. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	34
75	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	34
76	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. <i>Scientific Reports</i> , 2015, 5, 13028.	1.6	33
77	Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 1018-1023.	1.0	33
78	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. <i>Vaccines</i> , 2022, 10, 160.	2.1	33
79	Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. <i>Emerging Microbes and Infections</i> , 2022, 11, 368-383.	3.0	33
80	HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies. <i>PLoS ONE</i> , 2011, 6, e18233.	1.1	32
81	An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2533-2544.	1.3	32
82	Small molecule fusion inhibitors: Design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7539-7548.	1.4	32
83	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. <i>Viruses</i> , 2019, 11, 56.	1.5	31
84	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. <i>Protein and Cell</i> , 2021, 12, 84-88.	4.8	31
85	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. <i>Cell Research</i> , 2022, 32, 404-406.	5.7	31
86	Synergistic Effect Resulting From Combinations of a Bifunctional HIV-1 Antagonist With Antiretroviral Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 1-6.	0.9	30
87	Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction. <i>World Journal of Gastroenterology</i> , 2015, 21, 4852.	1.4	30
88	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. <i>Microbes and Infection</i> , 2015, 17, 142-148.	1.0	30
89	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. <i>Viruses</i> , 2019, 11, 705.	1.5	30
90	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. <i>Frontiers in Microbiology</i> , 2018, 9, 2643.	1.5	29

#	ARTICLE	IF	CITATIONS
91	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 132.	7.1	29
92	Dissolving microneedle-encapsulated drug-loaded nanoparticles and recombinant humanized collagen type III for the treatment of chronic wound <i>via</i> anti-inflammation and enhanced cell proliferation and angiogenesis. <i>Nanoscale</i> , 2022, 14, 1285-1295.	2.8	29
93	HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2012, 1818, 2950-2957.	1.4	28
94	The Adjuvanticity of an <i>O. volvulus</i> -Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates. <i>PLoS ONE</i> , 2012, 7, e37019.	1.1	28
95	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014, 1838, 1296-1305.	1.4	27
96	Rhinovirus respiratory tract infection in hospitalized adult patients is associated with T H 2 response irrespective of asthma. <i>Journal of Infection</i> , 2018, 76, 465-474.	1.7	27
97	Using gene expression databases for classical trait QTL candidate gene discovery in the BXD recombinant inbred genetic reference population: Mouse forebrain weight. <i>BMC Genomics</i> , 2008, 9, 444.	1.2	26
98	Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3284-3286.	1.0	26
99	Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles. <i>Aids</i> , 2016, 30, 827-838.	1.0	26
100	A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. <i>Aids</i> , 2017, 31, 885-894.	1.0	26
101	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. <i>Frontiers in Microbiology</i> , 2020, 11, 1063.	1.5	26
102	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	7.1	26
103	Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds. <i>Journal of Materials Chemistry B</i> , 2021, 9, 9684-9699.	2.9	26
104	Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. <i>Retrovirology</i> , 2010, 7, 37.	0.9	25
105	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. <i>Journal of Virology</i> , 2017, 91, .	1.5	25
106	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
107	Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket. <i>Journal of Virology</i> , 2012, 86, 589-593.	1.5	24
108	Design, Synthesis, and Biological Evaluation of Highly Potent Small Molecule- α -Peptide Conjugates as New HIV-1 Fusion Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2527-2539.	2.9	24

#	ARTICLE	IF	CITATIONS
109	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-12.	3.0	24
110	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 707-719.	2.4	24
111	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	5.7	24
112	A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. <i>Cell Research</i> , 2022, 32, 495-497.	5.7	24
113	Development of SARS vaccines and therapeutics is still needed. <i>Future Virology</i> , 2013, 8, 1-2.	0.9	23
114	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. <i>Molecules</i> , 2019, 24, 1134.	1.7	23
115	Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection in vivo. <i>Immunity</i> , 2021, 54, 2231-2244.e6.	6.6	23
116	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. <i>EBioMedicine</i> , 2022, 79, 103986.	2.7	23
117	HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. <i>Laboratory Investigation</i> , 2014, 94, 777-787.	1.7	22
118	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. <i>Frontiers of Medicine</i> , 2017, 11, 449-461.	1.5	22
119	A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. <i>Viruses</i> , 2022, 14, 597.	1.5	22
120	Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. <i>Microbes and Infection</i> , 2013, 15, 506-510.	1.0	21
121	ADS-J1 Inhibits Semen-Derived Amyloid Fibril Formation and Blocks Fibril-Mediated Enhancement of HIV-1 Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5123-5134.	1.4	21
122	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	3.0	21
123	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. <i>Cellular and Molecular Immunology</i> , 2019, 16, 757-769.	4.8	21
124	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	20
125	Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. <i>Microbes and Infection</i> , 2018, 20, 626-634.	1.0	20
126	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. <i>Viruses</i> , 2019, 11, 31.	1.5	20

#	ARTICLE	IF	CITATIONS
127	Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor. <i>Journal of Virology</i> , 2010, 84, 9359-9368.	1.5	19
128	Peptides derived from HIV-1 gp120 coreceptor binding domain form amyloid fibrils and enhance HIV-1 infection. <i>FEBS Letters</i> , 2014, 588, 1515-1522.	1.3	19
129	PA-356R is a unique signature of the avian influenza A (H7N9) viruses with bird-to-human transmissibility: Potential implication for animal surveillances. <i>Journal of Infection</i> , 2013, 67, 490-494.	1.7	18
130	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant. <i>Vaccines</i> , 2021, 9, 1442.	2.1	18
131	A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability. <i>Journal of Biological Chemistry</i> , 2011, 286, 28425-28434.	1.6	17
132	Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. <i>Journal of Virology</i> , 2015, 89, 6960-6964.	1.5	17
133	A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. <i>Microbes and Infection</i> , 2016, 18, 148-152.	1.0	17
134	Design, modeling and 3D printing of a personalized cervix tissue implant with protein release function. <i>Biomedical Materials (Bristol)</i> , 2020, 15, 045005.	1.7	17
135	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). <i>Cell Discovery</i> , 2021, 7, 109.	3.1	17
136	Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. <i>Chemical Communications</i> , 2012, 48, 11579.	2.2	16
137	Serological Investigation of Subclinical Influenza A(H7H9) Infection Among Healthcare and Non-Healthcare Workers in Zhejiang Province, China. <i>Clinical Infectious Diseases</i> , 2013, 57, 919-921.	2.9	16
138	Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. <i>Aids</i> , 2019, 33, 1545-1555.	1.0	16
139	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008082.	2.1	16
140	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11869.	1.8	16
141	Neutralization sensitivity of HIV-1 subtype B ¹ clinical isolates from former plasma donors in China. <i>Virology Journal</i> , 2013, 10, 10.	1.4	15
142	Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides ¹ anti-HIV activity. <i>Aids</i> , 2014, 28, 1251-1260.	1.0	15
143	Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. <i>Viruses</i> , 2022, 14, 501.	1.5	15
144	Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, e216-e226.	2.9	15

#	ARTICLE	IF	CITATIONS
145	Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. <i>Microbes and Infection</i> , 2017, 19, 597-604.	1.0	14
146	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. <i>ACS Infectious Diseases</i> , 2020, 6, 882-890.	1.8	14
147	A Nanoparticle-Encapsulated Non-Nucleoside Reverse-Transcriptase Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation Time in Plasma. <i>Current Pharmaceutical Design</i> , 2014, 21, 925-935.	0.9	14
148	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
149	Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1537-1545.	1.3	13
150	Adding an Artificial Tail Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. <i>Molecules</i> , 2017, 22, 1996.	1.7	13
151	Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. <i>Viruses</i> , 2019, 11, 1064.	1.5	13
152	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
153	A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. <i>Viruses</i> , 2022, 14, 549.	1.5	13
154	The cytoplasmic domain of influenza M2 protein interacts with caveolin-1. <i>Archives of Biochemistry and Biophysics</i> , 2009, 486, 150-154.	1.4	12
155	Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations. <i>Scientific Reports</i> , 2016, 6, 31983.	1.6	12
156	3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 573-576.	1.3	11
157	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). <i>Emerging Microbes and Infections</i> , 2015, 4, 1-2.	3.0	11
158	Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection. <i>Viruses</i> , 2015, 7, 798-819.	1.5	11
159	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. <i>Aids</i> , 2018, 32, 1749-1761.	1.0	11
160	Design and Biological Evaluation of <i>m</i> -Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8773-8783.	2.9	11
161	Microfibrillated cellulose-enhanced carboxymethyl chitosan/oxidized starch sponge for chronic diabetic wound repair. <i>Materials Science and Engineering C</i> , 2022, 135, 112669.	3.8	11
162	An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. <i>Chemical Science</i> , 2016, 7, 2145-2150.	3.7	10

#	ARTICLE	IF	CITATIONS
163	A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue. <i>Frontiers in Microbiology</i> , 2019, 10, 2250.	1.5	10
164	Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K ⁺ Channel Integrity. <i>Journal of Immunology</i> , 2019, 202, 3187-3197.	0.4	10
165	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	10
166	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. <i>Virologica Sinica</i> , 2020, 35, 340-343.	1.2	10
167	Interferon-gamma inhibits influenza A virus cellular attachment by reducing sialic acid cluster size. <i>IScience</i> , 2022, 25, 104037.	1.9	10
168	Important Changes in Biochemical Properties and Function of Mutated LLP12 Domain of HIV-1 gp41. <i>Chemical Biology and Drug Design</i> , 2007, 70, 311-318.	1.5	9
169	Combinations of 3-Hydroxyphthalic Anhydride-Modified Ovalbumin With Antiretroviral Drug-Based Microbicide Candidates Display Synergistic and Complementary Effects Against HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 384-392.	0.9	9
170	Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. <i>Journal of Infection</i> , 2013, 67, 156-158.	1.7	9
171	De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. <i>Chemical Science</i> , 2015, 6, 6505-6509.	3.7	9
172	Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. <i>Journal of Medical Virology</i> , 2016, 88, 1098-1101.	2.5	9
173	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-2.	3.0	9
174	A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. <i>Amino Acids</i> , 2016, 48, 2867-2873.	1.2	9
175	Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. <i>Scientific Reports</i> , 2016, 6, 32161.	1.6	9
176	A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 313-320.	1.9	9
177	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β -Coronavirus Infection. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2809-2819.	2.9	9
178	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. <i>Cell and Bioscience</i> , 2021, 11, 128.	2.1	9
179	A "Two-Birds-One-Stone" Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11460-11471.	2.9	9
180	Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines. <i>MSphere</i> , 2022, 7, e0091521.	1.3	9

#	ARTICLE	IF	CITATIONS
181	V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. <i>Vaccine</i> , 2008, 26, 845-852.	1.7	8
182	HIV-1 Glycoprotein 41 Ectodomain Induces Activation of the CD74 Protein-mediated Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway to Enhance Viral Infection. <i>Journal of Biological Chemistry</i> , 2011, 286, 44869-44877.	1.6	8
183	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	1.5	8
184	A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. <i>Viruses</i> , 2019, 11, 874.	1.5	8
185	A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. <i>Viruses</i> , 2022, 14, 655.	1.5	8
186	A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding. <i>Cell Research</i> , 2022, 32, 862-865.	5.7	8
187	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. <i>Journal of Infection</i> , 2017, 75, 68-71.	1.7	7
188	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 318.	7.1	7
189	Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. <i>Frontiers in Pharmacology</i> , 2020, 11, 613361.	1.6	7
190	The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants. <i>Viruses</i> , 2022, 14, 489.	1.5	7
191	Biosecurity and biosafety in research on emerging pathogens. <i>Emerging Microbes and Infections</i> , 2012, 1, 1-2.	3.0	6
192	Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure. <i>PLoS ONE</i> , 2013, 8, e66156.	1.1	6
193	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3719-3723.	1.0	6
194	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. <i>Frontiers in Microbiology</i> , 2018, 9, 2570.	1.5	6
195	Assessment of population susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging influenza virus strains. <i>Epidemiology and Infection</i> , 2019, 147, e279.	1.0	6
196	Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. <i>Vaccines</i> , 2020, 8, 754.	2.1	6
197	Viral Entry Inhibitors Targeting Six-Helical Bundle Core against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins. <i>Current Medicinal Chemistry</i> , 2022, 29, 700-718.	1.2	6
198	The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry. <i>PLoS ONE</i> , 2012, 7, e44874.	1.1	6

#	ARTICLE	IF	CITATIONS
199	The Outbreak of Avian Influenza A (H7N9) in China: Current Status and Future Prospects. <i>Biomedical Journal</i> , 2013, 36, 96.	1.4	6
200	Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant. <i>Diagnostics</i> , 2021, 11, 2216.	1.3	6
201	Long-Acting Protective Ocular Surface by Instilling Adhesive Dual-Antiviral Nanoparticles. <i>Advanced Healthcare Materials</i> , 2022, , 2200283.	3.9	6
202	Highly Pathogenic Avian Influenza A(H5N1) Mutants Transmissible by Air Are Susceptible to Human and Animal Neutralizing Antibodies. <i>Journal of Infectious Diseases</i> , 2013, 208, 1315-1319.	1.9	5
203	Receptor Binding Domain Based HIV Vaccines. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	5
204	Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. <i>Microbes and Infection</i> , 2015, 17, 135-141.	1.0	5
205	Up or down: where comes Omicron?. <i>Cell Research</i> , 2022, 32, 601-602.	5.7	5
206	F(ab ²) fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. <i>Microbes and Infection</i> , 2013, 15, 887-894.	1.0	4
207	Immunoengineered adjuvants for universal vaccines against respiratory viruses. <i>Fundamental Research</i> , 2021, 1, 189-192.	1.6	4
208	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. <i>Molecules</i> , 2021, 26, 1964.	1.7	4
209	High compliance to infection control measures prevented guest-to-staff transmission in COVID-19 quarantine hotels. <i>Journal of Infection</i> , 2021, , .	1.7	4
210	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. <i>MBio</i> , 2022, 13, e0338421.	1.8	4
211	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. <i>Lancet, The</i> , 2015, 386, S44.	6.3	3
212	Poly(U) and CpG ameliorate the unbalanced T cell immunity and pneumonia of mice with RSV vaccine-enhanced disease. <i>BioScience Trends</i> , 2017, 11, 450-459.	1.1	3
213	Neutralizing SARS-CoV-2 by dimeric side chain-to-side chain cross-linked ACE2 peptide mimetics. <i>Chemical Communications</i> , 2022, 58, 1804-1807.	2.2	3
214	Tactics used by HIV-1 to evade host innate, adaptive, and intrinsic immunities. <i>Chinese Medical Journal</i> , 2013, 126, 2374-9.	0.9	3
215	Coronavirus Entry Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 101-121.	0.8	3
216	Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. <i>Cellular and Molecular Immunology</i> , 2017, 14, 568-571.	4.8	2

#	ARTICLE	IF	CITATIONS
217	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-4.	3.0	2
218	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. <i>Microbes and Infection</i> , 2021, 23, 104840.	1.0	2
219	Controlling HIV sexual transmission: a major challenge for China's new leadership. <i>Cell and Bioscience</i> , 2013, 3, 17.	2.1	1
220	Design of artificial α -helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114336.	2.6	1
221	The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: Involvement in viral fusion. <i>Science Bulletin</i> , 2009, 54, 1707-1712.	4.3	0
222	An artificial peptide-based HIV-1 fusion inhibitor containing M-T hook structure exhibiting improved antiviral potency and drug resistance profile. <i>Future Virology</i> , 2015, 10, 961-969.	0.9	0
223	Normal human sera contain heat-sensitive factor(s) to enhance H7N9 influenza virus infection. <i>Journal of Infection</i> , 2016, 72, 123-125.	1.7	0
224	P848â€¦Revisiting enfuvirtideâ€™s mechanism and designing its analog with improved activity by targeting triple sites in gp41. , 2019, , .		0
225	Fusion. , 2013, , 1-9.		0
226	Intra-amniotic Injection of Mouse Embryos. <i>Bio-protocol</i> , 2018, 8, e2854.	0.2	0
227	Fusion. , 2018, , 564-571.		0
228	A Potent Germline-Like Human Monoclonal Antibody Targeting a Novel pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
229	A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile. <i>Pharmaceuticals</i> , 2022, 15, 424.	1.7	0